Brian Jerkins, MD
Ophthalmology · Memphis, TNNPI 1487829347
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $117,792 of the $150,377 with a category attached, or 78.3%. 16 manufacturers reported payments, led by AbbVie at 56.0% of the total. Reporting peaked in 2022 at $33,524 and has fallen 94.0% since, to $1,995 in 2025. Among ophthalmology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $418.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$84K
- Aerie Pharmaceuticals, Inc.$31K
- Alcon$19K
- Iridex Corporation$8K
- NEW World Medical,inc.$3K
- Ocular Therapeutix, Inc.$3K
- plus $1K from 10 others
Across 17 payments — averaging $3445.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$32K
- Ocular Therapeutix, Inc.$27K
What the payments were for
- Consulting fees$10,5757%
- Speaking & faculty fees$117,79278%
- Travel & lodging$13,1469%
- Food & beverage$8,4996%
- Education$3200%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 181 | $84,282 |
| Aerie Pharmaceuticals, Inc. | 67 | $31,157 |
| Alcon | 36 | $19,465 |
| Iridex Corporation | 4 | $8,000 |
| NEW World Medical,inc. | 4 | $3,198 |
| Ocular Therapeutix, Inc. | 11 | $2,936 |
| Bausch & Lomb Americas Inc. | 11 | $304 |
| Amgen(2 entities) | 11 | $254 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $162 |
| Novartis | 10 | $161 |
| Carl Zeiss Meditec, Inc. | 1 | $115 |
| Thea Pharma Inc. | 5 | $99 |
| Biotissue Holdings Inc. | 5 | $89 |
| UCB, Inc. | 2 | $74 |
| Sun Pharmaceutical Industries Inc. | 3 | $40 |
| Eyevance Pharmaceuticals LLC | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$48,848
- Rocklatan$47,802
- DURYSTA$44,024
- LUMIGAN$28,975
- SIMBRINZA$16,367
- COMBIGAN$11,222
- XEN$5,472
- DEXTENZA$2,747
- ALPHAGAN P$2,000
- Ahmed Glaucoma Valve$1,623
- Kahook Dual Blade$1,623
- XEN GLAUCOMA TREATMENT SYSTEM$376
- AcrySof$246
- Streamline Surgical System$123
- IOLMaster 500$115
- VYZULTA$104
How this compares
$150,377 in reported general payments places this provider in the 95th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 512 | $231,428 |
| RocklatanNetarsudil Mesylat/Latanoprost | 410 | $207,366 |
| RhopressaNetarsudil Mesylate | 287 | $147,199 |
| CombiganBrimonidine Tartrate/Timolol | 335 | $125,373 |
| VyzultaLatanoprostene Bunod | 283 | $122,673 |
| RestasisCyclosporine | 68 | $64,290 |
| Alphagan PBrimonidine Tartrate | 84 | $37,756 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 177 | $36,874 |
| Brimonidine Tartrate | 359 | $20,506 |
| Travoprost | 101 | $18,681 |
| Brinzolamide | 73 | $16,273 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 829 | $15,208 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 54 | $14,930 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 71 | $12,436 |
| Timolol Maleate | 607 | $11,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $84,282 | $458,847999 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $31,157 | $354,565697 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $304 | $122,673283 claims |
| AlconSimbrinza | $19,465 | $14,93054 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $162 | $11,16848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Memphis
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian FowlerMemphis$206K
- James FreemanMemphis$141K
- John FreemanMemphis$136K
- Penny AsbellMemphis$131K
- Kourtney HouserMemphis$104K
- Subba GollamudiMemphis$67K
- Andrew CrothersMemphis$13K
- Brian SmithMemphis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.